Welcome to our dedicated page for Pacira Biosciences SEC filings (Ticker: PCRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pacira BioSciences, Inc. (NASDAQ: PCRX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, along with AI-powered tools to help interpret complex documents. Pacira is a pharmaceutical preparation manufacturing company focused on non-opioid pain therapies, and its filings give detailed insight into how it manages product commercialization, manufacturing, financing and governance.
Pacira’s current reports on Form 8‑K cover topics such as quarterly financial results, workforce reductions tied to manufacturing efficiencies for EXPAREL, and a senior secured revolving credit facility used to refinance prior indebtedness and support working capital. One 8‑K describes the company’s investment in large-scale manufacturing suites in San Diego, California, and Swindon, United Kingdom, and the decision to decommission an earlier 45‑liter batch suite, while another outlines the terms of its credit agreement with lenders.
Investors reviewing Pacira’s filings typically focus on annual reports on Form 10‑K and quarterly reports on Form 10‑Q for information about its commercial products—EXPAREL, ZILRETTA and iovera°—and its clinical-stage gene therapy candidate PCRX-201. These filings generally discuss revenue composition, research and development activities, manufacturing capacity, risk factors and intellectual property, including patent protection for EXPAREL described in company press releases.
Forms 8‑K also document material events such as share repurchase authorizations, inducement equity grants under the company’s inducement plan, credit facility amendments and other significant corporate actions. For users interested in insider activity, Forms 3, 4 and 5 provide data on transactions by directors, officers and major shareholders, while proxy statements explain executive compensation and board matters.
On Stock Titan, AI-generated summaries help explain lengthy filings, highlight key changes from prior periods and surface items that may affect Pacira’s financial position or strategy. Real-time updates from EDGAR ensure that new 10‑K, 10‑Q, 8‑K and Form 4 filings for PCRX are quickly available, allowing investors to track developments in Pacira’s non-opioid pain portfolio, manufacturing initiatives and capital structure without reading every page manually.
Pacira BioSciences Chief Commercial Officer Brendan Teehan acquired additional company stock through an employee purchase plan. On 12/31/2025, he obtained 402.268 shares of Pacira common stock at a price of $10.763 per share under the issuer's employee stock purchase plan.
After this transaction, Teehan directly beneficially owned a total of 54,402.268 shares of Pacira common stock, reflecting his ongoing equity participation as an executive officer.
Pacira BioSciences, Inc. (PCRX) reported an insider stock sale by its Chief Medical Officer. On 11/17/2025, the officer sold 3,960 shares of Pacira common stock at a price of $24.09 per share, according to a Form 4 filing. After this transaction, the officer directly beneficially owned 178,367.009 shares of Pacira common stock.
The filing states that this sale was carried out under a Rule 10b5-1 trading plan, which is a pre-arranged plan for buying or selling stock that is intended to comply with securities regulations and provide an affirmative defense against insider trading claims.
Pacira BioSciences (PCRX) disclosed that its Chief Financial Officer sold 12,060 shares of common stock at $22.09 per share on 11/10/2025.
The transaction was executed under a Rule 10b5-1 trading plan. After this sale, the CFO beneficially owns 56,250 shares, held directly.
Pacira BioSciences reported quarterly results for the period ended September 30, 2025. Total revenues were $179.5 million, up from $168.6 million a year ago, driven by net product sales of $178.0 million. EXPAREL led with $139.9 million, followed by ZILRETTA at $29.0 million and iovera° at $6.5 million.
The company posted net income of $5.4 million versus a prior-year loss that included a goodwill impairment. Operating expenses fell sharply year over year, with no goodwill impairment this quarter but including a $25.9 million impairment to indefinite‑lived IPR&D tied to ZILRETTA shoulder OA. Nine‑month cash from operations was $108.3 million.
Pacira reshaped its balance sheet: it repaid $202.5 million of 2025 convertible notes at maturity, terminated its Term Loan A, and established a $300.0 million revolving credit facility, with $96.0 million outstanding at quarter‑end. Cash and cash equivalents were $147.6 million and short‑term investments $98.7 million. The company also repurchased $50.0 million of stock in the quarter, bringing year‑to‑date repurchases to $100.4 million; shares outstanding were 42,965,902 as of September 30, 2025.
Pacira BioSciences, Inc. furnished a press release announcing its financial results for the third quarter ended September 30, 2025. The full text is included as Exhibit 99.1.
The company states the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed filed under the Exchange Act. PCRX common stock trades on the Nasdaq Global Select Market.
Pacira BioSciences (PCRX) reported an insider tax-withholding transaction by its CFO. On 10/31/2025, 6,690 shares of common stock were withheld by the company at $21.38 to cover taxes due upon restricted stock unit vesting.
Following the withholding, the officer directly beneficially owns 68,310 shares. The filing lists the transaction code as F, which denotes shares withheld for tax obligations related to equity awards.
Ceesay Abraham, a director of Pacira BioSciences, Inc. (PCRX), reported a sale of 2,354 shares of the issuer's common stock on 09/04/2025 at a price of $27.19 per share, executed under a previously adopted Rule 10b5-1 trading plan. After the reported disposition, the reporting person beneficially owns 9,039 shares. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact on 09/08/2025. The filing indicates the transaction code S (sale) and explicitly states the sale was effected pursuant to the 10b5-1 plan.
Pacira BioSciences (PCRX) Form 144: The filer notifies a proposed sale of 2,354 shares of common stock acquired on 06/12/2025 upon restricted stock vesting. The shares are to be sold through Fidelity Brokerage Services LLC with an approximate aggregate market value of $64,005.26 and an indicated approximate sale date of 09/04/2025. The filing reports 44,932,721 shares outstanding for the issuer. No securities were reported sold in the prior three months. The filer represents they are unaware of undisclosed material adverse information.
Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation reported beneficial ownership of 2,395,601 shares of Pacira BioSciences common stock, representing 5.34% of the outstanding class. The filing states the reporting persons have sole voting and sole dispositive power over these shares. It also notes that certain funds managed by Renaissance have the right to receive dividends and proceeds from the sale of the securities. The statement certifies the shares are held in the ordinary course of business and were not acquired to change or influence control of the issuer.
This disclosure crosses the 5% reporting threshold and provides clarity on who controls the position without indicating an activist intent.
Pacira BioSciences director Bigal Marcelo reported a sale of 4,912 shares of common stock at $23.67 per share on 08/07/2025, reducing his direct holding to 11,393 shares. The Form 4 discloses no derivative transactions. The filing documents an insider sale and the remaining direct beneficial ownership reported by the director.